Trial Profile

A clinical study of AR-1105 in Diabetic macular oedema (DME)

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 15 Mar 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

04 Nov 2021 According to an Aerie Pharmaceuticals media release, the company expect to begin Phase 3 activities in the first half of 2022 after having discussions with both the FDA and European Medicines Agency to finalize Phase 3 strategy for sustained-release implant, AR-1105. Supply chain issues for implant injector components have caused the date to be moved from the last quarter of this year.
08 Apr 2021 According to an Aerie Pharmaceuticals media release, the company continue discussions with both the FDA and EMA to finalize a Phase 3 strategy for our sustained-release retinal implant, AR-1105, and expect to begin Phase 3 activities by year-end of 2021.
03 Nov 2019 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com